CBI

From OncoWiki
Jump to: navigation, search

Indication

Chemotherapy for stage IV (metastatic) cancer

  • Cetuximab (Erbitux) 400 mg/m2 iv loading, then 250 mg/m2 iv qw
  • Bevacizumab (Avastin) 5 mg/kg iv q2w
  • Irinotecan (Camptosar, CPT-11) 350 mg/m2 iv q3w or 180 mg/m2 iv q2w or 125 mg/m2 iv qw x 4 wks every 6 wks

References

Saltz LB et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) verus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. 2005 ASCO annual meeting. Abstract 3508